|
Gene: MCM4 |
Gene summary for MCM4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MCM4 | Gene ID | 4173 |
Gene name | minichromosome maintenance complex component 4 | |
Gene Alias | CDC21 | |
Cytomap | 8q11.21 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | B4DLA6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4173 | MCM4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.36e-06 | 3.38e-01 | -0.0811 |
4173 | MCM4 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.32e-02 | 2.20e-01 | -0.1088 |
4173 | MCM4 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.07e-06 | 2.47e-01 | -0.1954 |
4173 | MCM4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.07e-09 | 4.60e-01 | -0.059 |
4173 | MCM4 | HTA11_7663_2000001011 | Human | Colorectum | SER | 8.62e-03 | 2.45e-01 | 0.0131 |
4173 | MCM4 | HTA11_6801_2000001011 | Human | Colorectum | SER | 7.48e-04 | 5.81e-01 | 0.0171 |
4173 | MCM4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.94e-06 | 3.50e-01 | 0.294 |
4173 | MCM4 | LZE2T | Human | Esophagus | ESCC | 1.62e-07 | 1.08e+00 | 0.082 |
4173 | MCM4 | LZE7T | Human | Esophagus | ESCC | 4.27e-04 | 2.66e-01 | 0.0667 |
4173 | MCM4 | LZE20T | Human | Esophagus | ESCC | 2.02e-05 | 2.82e-01 | 0.0662 |
4173 | MCM4 | LZE24T | Human | Esophagus | ESCC | 2.39e-07 | 2.68e-01 | 0.0596 |
4173 | MCM4 | LZE21T | Human | Esophagus | ESCC | 1.34e-03 | 3.12e-01 | 0.0655 |
4173 | MCM4 | LZE6T | Human | Esophagus | ESCC | 2.08e-02 | 2.51e-01 | 0.0845 |
4173 | MCM4 | P1T-E | Human | Esophagus | ESCC | 2.37e-05 | 4.08e-01 | 0.0875 |
4173 | MCM4 | P2T-E | Human | Esophagus | ESCC | 7.75e-37 | 9.13e-01 | 0.1177 |
4173 | MCM4 | P4T-E | Human | Esophagus | ESCC | 6.68e-23 | 6.64e-01 | 0.1323 |
4173 | MCM4 | P5T-E | Human | Esophagus | ESCC | 1.49e-11 | 2.08e-01 | 0.1327 |
4173 | MCM4 | P8T-E | Human | Esophagus | ESCC | 3.42e-04 | 2.48e-01 | 0.0889 |
4173 | MCM4 | P9T-E | Human | Esophagus | ESCC | 2.12e-09 | 2.33e-01 | 0.1131 |
4173 | MCM4 | P10T-E | Human | Esophagus | ESCC | 6.78e-13 | 4.01e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0032392 | Colorectum | AD | DNA geometric change | 31/3918 | 90/18723 | 2.02e-03 | 1.63e-02 | 31 |
GO:00323921 | Colorectum | MSS | DNA geometric change | 29/3467 | 90/18723 | 1.26e-03 | 1.20e-02 | 29 |
GO:0006302 | Colorectum | MSS | double-strand break repair | 64/3467 | 251/18723 | 3.58e-03 | 2.65e-02 | 64 |
GO:0032508 | Colorectum | MSS | DNA duplex unwinding | 25/3467 | 84/18723 | 8.27e-03 | 4.99e-02 | 25 |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:00062612 | Esophagus | ESCC | DNA-dependent DNA replication | 100/8552 | 151/18723 | 2.61e-07 | 3.94e-06 | 100 |
GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
GO:00062701 | Esophagus | ESCC | DNA replication initiation | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
GO:00007241 | Esophagus | ESCC | double-strand break repair via homologous recombination | 79/8552 | 138/18723 | 4.05e-03 | 1.62e-02 | 79 |
GO:00007251 | Esophagus | ESCC | recombinational repair | 80/8552 | 140/18723 | 4.10e-03 | 1.63e-02 | 80 |
GO:1902969 | Esophagus | ESCC | mitotic DNA replication | 11/8552 | 14/18723 | 1.30e-02 | 4.27e-02 | 11 |
GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
GO:00325081 | Liver | HCC | DNA duplex unwinding | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
GO:0006261 | Liver | HCC | DNA-dependent DNA replication | 80/7958 | 151/18723 | 5.91e-03 | 2.44e-02 | 80 |
GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa030304 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0303011 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa03030 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa030301 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
hsa030302 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
hsa0411022 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
hsa030303 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
hsa0411032 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MCM4 | SNV | Missense_Mutation | novel | c.1400C>A | p.Ala467Asp | p.A467D | P33991 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MCM4 | SNV | Missense_Mutation | rs773264700 | c.1501C>T | p.Arg501Trp | p.R501W | P33991 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MCM4 | insertion | Frame_Shift_Ins | novel | c.1878_1879insA | p.Thr629AsnfsTer4 | p.T629Nfs*4 | P33991 | protein_coding | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
MCM4 | SNV | Missense_Mutation | c.1823A>T | p.Asn608Ile | p.N608I | P33991 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-5C-A9VH-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MCM4 | SNV | Missense_Mutation | c.1720N>T | p.Asp574Tyr | p.D574Y | P33991 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BC-4073-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | SD | |
MCM4 | SNV | Missense_Mutation | rs755044869 | c.199N>A | p.Val67Met | p.V67M | P33991 | protein_coding | tolerated(0.28) | benign(0.047) | TCGA-DD-A4NF-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MCM4 | SNV | Missense_Mutation | novel | c.1741G>A | p.Glu581Lys | p.E581K | P33991 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
MCM4 | SNV | Missense_Mutation | novel | c.956G>T | p.Arg319Leu | p.R319L | P33991 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-38-4631-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MCM4 | SNV | Missense_Mutation | c.1712G>T | p.Cys571Phe | p.C571F | P33991 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-44-7671-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
MCM4 | SNV | Missense_Mutation | c.1729G>T | p.Asp577Tyr | p.D577Y | P33991 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-49-4506-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |